SuperworthRafael revenue RFL
Sales by quarter and over the last twelve months, from 2016.
- Last 12 months, to Apr 30, 2026
- $980K
- Latest quarter, Q3 FY26
- $179K
- −51% on a year earlier
- Fiscal year 2025
- $917K
- +44% on the year before
Rafael's revenue was $980K over the twelve months to Apr 30, 2026, up 34% on a year earlier.
In its latest quarter, Q3 FY26, it was $179K, down 51% on the same quarter a year before.
Over the five fiscal years to FY2025 it shrank 29% a year on average.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 | $917K | +44% |
| FY2024 | $637K | +128% |
| FY2023 | $279K | −32% |
| FY2022 | $410K | −90% |
| FY2021 | $4M | −19% |
| FY2020 | $4.9M | −0% |
| FY2019 | $4.9M | +13% |
| FY2018 | $4.4M | −22% |
| FY2017 | $5.6M | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY26 | $179K | −51% | $980K | |
| Q2 FY26 | $211K | +174% | $1.2M | |
| Q1 FY26 | $240K | +88% | $1M | |
| Q4 FY25 | $350K | +112% | $917K | |
| Q3 FY25 | $362K | +8% | $732K | |
| Q2 FY25 | $77K | +13% | $706K | |
| Q1 FY25 | $128K | +88% | $697K | |
| Q4 FY24 | $165K | +143% | $637K | |
| Q3 FY24 | $336K | +373% | $540K | |
| Q2 FY24 | $68K | −3% | $275K | |
| Q1 FY24 | $68K | −3% | $277K | |
| Q4 FY23 | $68K | −1% | $279K |
Against its peers
Companies in Drug Manufacturers - General nearest Rafael's size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| RFLRafael | $980K | +34% a year |
| SPROSpero Therapeutics | $47M | −3% a year |
| LFVNLifevantage | $182.6M | −20% a year |
| ATNMActinium Pharmaceuticals | n/m | |
| NATRNatures Sunshine Products | $492M | +7% a year |
| ARVNArvinas | $316.7M | −15% a year |
| PBYIPuma Biotechnology | $231.2M | −3% a year |
| IRWDIronwood Pharmaceuticals | $389.3M | +26% a year |
| ZVRAZevra Therapeutics | $136.1M | +119% a year |
| CRMDCorMedix | $462.2M | +281% a year |
| Peer median | $274M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Rafael
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.